Madrigal Pharmaceuticals (MDGL) Net Income (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Net Income for 17 consecutive years, with -$57.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income fell 35.17% year-over-year to -$57.1 million; the TTM figure through Jun 2026 stood at -$432.5 million (down 61.2% YoY), while the FY2025 annual figure was -$853.8 million, up 11.07% from the prior year.
• Net Income rose to -$57.1 million in Q2 2026 per MDGL's latest filing, from -$92.3 million in the prior quarter.
• Across five years, Net Income topped out at -$42.3 million in Q2 2025 and bottomed at -$172.0 million in Q4 2025.
• Historically, Net Income has averaged -$92.7 million across 5 years, with a median of -$85.9 million in 2022.
• On a YoY basis, Net Income climbed as much as 72.18% in 2025 and fell as far as 275.12% in 2025.
• Madrigal Pharmaceuticals' Net Income stood at -$85.9 million in 2022, then sank by 30.6% to -$112.2 million in 2023, then soared by 59.14% to -$45.8 million in 2024, then tumbled by 275.12% to -$172.0 million in 2025, then soared by 66.77% to -$57.1 million in 2026.
• Business Quant data shows MDGL's Net Income at -$57.1 million in Q2 2026, -$92.3 million in Q1 2026, and -$172.0 million in Q4 2025.